← Back to Clinical Trials
Recruiting NCT05945576

NCT05945576 IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05945576
Status Recruiting
Phase
Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Condition Silver Russell Syndrome
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2017-03-10
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2017-03-10 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile in all patients (adults and children) affected with an ID regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center. The main questions it aims to answer are: * Can we identify common metabolic profiles for all imprinted diseases? * Which imprinting disorders have an impact on the metabolic profiles of IDs? * Which are the metabolic risks associated to IDs? * Can we use the metabolic profiles for the clinical classification and prognosis of IDs? * Are there common therapeutic approaches for all IDs?

Eligibility Criteria

Inclusion Criteria: * Patients (adults and children) affected with an ID regardless of the severity of the disease * A confirmed diagnosis of ID (based on molecular diagnosis) * A signed informed consent for adults or signed informed consent of parents/guardians of minors/ protected adult. Non-Inclusion Criteria: There are no non-inclusion criteria.

Contact & Investigator

Central Contact

Agnès LINGLART

✉ agnes.linglart@aphp.fr

📞 +33 1 45 21 78 53

Principal Investigator

Agnès LINGLART

PRINCIPAL INVESTIGATOR

Inserm U1169

Frequently Asked Questions

Who can join the NCT05945576 clinical trial?

This trial is open to participants of all sexes, studying Silver Russell Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05945576 currently recruiting?

Yes, NCT05945576 is actively recruiting participants. Contact the research team at agnes.linglart@aphp.fr for enrollment information.

Where is the NCT05945576 trial being conducted?

This trial is being conducted at Angers, France, Besançon, France, Clermont-Ferrand, France, Le Kremlin-Bicêtre, France and 11 additional locations.

Who is sponsoring the NCT05945576 clinical trial?

NCT05945576 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The principal investigator is Agnès LINGLART at Inserm U1169. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology